Actimmune Registry
PreclinicalSmall molecule
Actimmune Registry is one of 10 small molecule programs targeting Osteopetrosis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Osteopetrosis
#DrugCompanyPhaseTrials
1Clolar
GGenzyme, a Sanofi Company
Approved
Rocaltrol
Alnylam PharmaceuticalsPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Interferon-Gamma
SSPP Pharmaclon Ltd.
Phase 3
Campath 1h
Mario Negri Institute for Pharmacological ResearchPhase 3
Fludarabine Monophosphate
SSt. Petersburg State Pavlov Medical University
Phase 3
Busulfex
Akero TherapeuticsPhase 2
Actimmune
HHorizon Therapeutics Ireland DAC
Preclinical
Actimmune Registry
IInterMune
Preclinical
Systemic Chemotherapy and Antibodies
SSt. Jude Children's Research Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Actimmune Registry. EMBL-EBI & Wellcome Sanger Institute.
- [4]